Supplemental Table 1. Clinical characteristics according to the cumulative dose of RAI
RAI ()
RAI ()
High-active
Very-high-active
22.3-37.0 GBq
N=44
37.1- GBq
N=69
P-value
N=1072
(1.1-5.55 GBq)
N=981
Intermediateactive
(5.56-22.2 GBq)
N=302
44.8 ± 13.4
48.7 ± 12.5
45.8 ± 13.9
46.1 ± 15.8
40.2 ± 16.4
<0.001
926 (86.4)
829 (84.5)
239 (79.1)
31 (70.5)
51 (73.9)
<0.001
Low-active
Age at diagnosis of DTC,
yrs
Female, n (%)
T stage, n (%)
<0.001
T1
680 (71.4)
534 (63.4)
143 (49.0)
19 (45.2)
25 (45.5)
T2
225 (23.6)
244 (29.0)
115 (39.4)
14 (33.3)
25 (45.5)
T3
47 (4.9)
64 (7.6)
34 (11.6)
9 (21.4)
5 (9.1)
N stage, n (%)
N1
<0.001
155 (28.2)
428 (44.1)
180 (64.2)
27 (66.2)
42 (60.0)
M stage, n (%)
M1
<0.001
0 (0.0)
26 (3.1)
31 (13.9)
9 (24.3)
12 (26.1)
Disease status
NED
<0.001
575 (53.6)
524 (53.4)
130 (43.0)
13 (29.5)
16 (23.2)
Persistent
1 (0.1)
34 (3.5)
27 (8.9)
7 (15.9)
19 (27.5)
Recurrence
56 (5.2)
151 (15.4)
66 (21.9)
14 (31.8)
24 (34.8)
Supplemental Table 2. Types of SPM in thyroid cancer patients compared to that of cancer in general population according to the different
periods of SPM developments.
1990-1999
2000-2009
SPM in the present study
(Occurrence rate per 100)
General Cancer type
(Incidence rate per 100,000)a
SPM in the present study
(Occurrence rate per 100)
General Cancer type
(Incidence rate per 100,000)b
Bladder (0.6)
Stomach (0.6)
Liver (0.6)
Meninx (0.6)
Stomach (66.2)
Colorectal (26.2)
Lung (51.4)
Liver (46.8)
Bladder (9.0)
Stomach (1.5)
Hematologic (1.5)
Lung (1.5)
Liver (0.5)
Colorectal (0.5)
Stomach (66.9)
Lung (50.9)
Liver (42.6)
Colorectal (41.1)
Prostate (15.7)
Breast (0.6)
Stomach (26.7)
Breast (1.2)
Hematologic (0.2)
Breast (20.9)
Hematologic (0.7)
Stomach (0.1)
Colorectal (16.4)
Stomach (0.5)
Lung (0.1)
Cervix Uteri (16.3)
Pancreas(0.3)
Bladder (0.1)
Liver (12.3)
Bladder (0.2)
a
b
Cancer incidence rates, 1999 and Cancer incidence rates, 2005, Statistics Korea
Thyroid (35.3)
Breast (32.0)
Stomach (26.8)
Colorectal (23.0)
Lung (13.5)
Male
Female
Supplemental Table 3. Risk factors associated with SPM in patients who received 37.1 GBq or more RAI
SPM ()
SPM (+)
58
11
42 (72.4)
9 (81.8)
0.715
Age at diagnosis of thyroid carcinoma
40.9 ± 16.2
36.6 ± 17.6
0.435
Age at the initial RAI Treatment (yrs)
41.8 ± 15.7
34.7 ± 12.5
0.163
Total duration for RAI Treatment (months)
60 [5,232]
83[19,341]
0.123
9 [2,20]
12 [5,20]
0.388
Total iodine dose (GBq)
69.7 ± 24.6
92.5 ± 38.3
0.082
Body weight (kg)
60.4 ± 10.1
48.7 ± 10.0*
0.001*
Total iodine dose per weight (GBq/kg)
1.2 ± 0.4
2.0 ± 0.8*
0.009*
Serum Creatinine (mg/dL)
0.8 ± 0.1
0.9 ± 0.2
0.301
Number
Sex, female N (%)
Total number of RAI Treatment
P-value
CCr
97.1 ± 30.5
73.2 ± 21.9*
0.018*
CCr obtained by the Cockroft-vault equation: (140 – age)ⅹ body weight/72 ⅹ Serum creatinine